Effects of renal denervation on kidney function in patients with chronic kidney disease: a systematic review and meta-analysis

The present study aims to evaluate the clinical outcomes following renal denervation (RDN) for hypertensive patients with chronic kidney disease (CKD). Prospective studies published between January 1, 2010 and November 15, 2022 where systematically identified for RDN outcomes on office and ambulator...

Full description

Saved in:
Bibliographic Details
Published in:Journal of human hypertension 2024-01, Vol.38 (1), p.29-44
Main Authors: Mohammad, Ahmed A., Nawar, Khaled, Binks, Olivia, Abdulla, Mohammed H.
Format: Article
Language:English
Subjects:
692/699/1585/104
692/699/75/243
Blood pressure
Blood Pressure - physiology
Blood Pressure Monitoring, Ambulatory
Chronic illnesses
Clinical outcomes
Clinical trials
Creatinine
Denervation
Epidemiology
Epidermal growth factor receptors
Glomerular filtration rate
Health Administration
Humans
Hypertension
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - surgery
Kidney
Kidney diseases
Kidneys
Medicine
Medicine & Public Health
Meta-analysis
Patients
Prospective Studies
Public Health
Renal function
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - surgery
Review
Review Article
Sympathectomy - adverse effects
Sympathectomy - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aims to evaluate the clinical outcomes following renal denervation (RDN) for hypertensive patients with chronic kidney disease (CKD). Prospective studies published between January 1, 2010 and November 15, 2022 where systematically identified for RDN outcomes on office and ambulatory blood pressure, estimated glomerular filtration rate (eGFR), creatinine and procedural characteristics from three online databases (Medline, PubMed, EMBASE). Random effects model to combine risk ratios and mean differences was used. Where possible, clinical outcomes were pooled and analyzed at 6, 12 and 24 months. Significance was set at p  ≤ 0.05. 11 prospective trials, with a total of 226 patients with treatment resistant HTN receiving RDN met the inclusion criteria. Age ranged from 42.5 ± 13.8 to 66 ± 9. Main findings of this review included a reduction in systolic and diastolic office blood pressure at 6 [−19.8 ( p  
ISSN:1476-5527
0950-9240
1476-5527
DOI:10.1038/s41371-023-00857-3